MedTrace Logo

Anti-platelet + Pembro for H&N Tumors

NCT03245489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-31

No results posted yet for this study

Summary

The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Conditions

Interventions

DRUG

Pembrolizumab

200mg intravenous (IV) over 30 minutes

DRUG

Clopidogrel

75mg/day oral

DRUG

acetylsalicylic acid

81mg/day oral

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • John Kaczmar, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-06
Primary Completion
2023-11-20
Completion
2024-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245489 on ClinicalTrials.gov